RGEN - Repligen Stock Price Can Keep Growing: Buy The Current Dip
Investment Thesis
I like the look of Repligen (RGEN). The company operates in a growing market, supplying tools for the manufacture of biologic drugs, most notably monoclonal antibodies. It has a proven ability to make strategic acquisitions that complement its business model and capabilities and has cash available for further acquisitions having recently raised $600m via debt and equity offerings.
Its organic growth has recently exceeded 30% and exceeds 40% when recent acquisitions are factored in. Although the stock is relatively expensive, with much of the future value (I believe) already factored into the price,